Home › Targets › KRAS G12

KRAS G12 (1 companies · 2 programs)

Companies with an active program directed at KRAS G12.

Revolution Medicines, Inc. RVMD

RASONQUE — Pancreatic Ductal Adenocarcinoma Approved
RASONQUE — Non-Small Cell Lung Cancer NDA Submitted